AllianceBernstein’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

AllianceBernstein’s Portfolio SIOX Stock Details SIOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-12,063	Closed	-$128K	–	3155
2018 Q1	$128K	Sell	12,063 -1,512	-11%	-$24.3K	﹤0.01%	2938
2017 Q4	$572K	Buy	13,575 +7,075	+109%	+$317K	﹤0.01%	2489
2017 Q3	$358K	Hold	6,500	–	–	﹤0.01%	2694
2017 Q2	$1.21M	Buy	6,500 +1,287	+25%	+$226K	﹤0.01%	2204
2017 Q1	$623K	Sell	5,213 -625	-11%	-$65.5K	﹤0.01%	2456
2016 Q4	$580K	Hold	5,838	–	–	﹤0.01%	2517
2016 Q3	$654K	Hold	5,838	–	–	﹤0.01%	2419
2016 Q2	$600K	Buy	5,838 +3,663	+168%	+$366K	﹤0.01%	2449
2016 Q1	$200K	Buy	+2,175	New	+$232K	﹤0.01%	2720

Other funds holding SIOX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AllianceBernstein's SIOX Position: Q2 2018 in Review

AllianceBernstein sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q2 2018, closing a stake of 12,063 shares — an estimated $128K sold.

AllianceBernstein first reported a position in SIOX in Q1 2016 and held it in 9 quarters. The position peaked at $1.21M in Q2 2017. 71 funds tracked by Wall St. Rank hold SIOX as of Q2 2018.

AllianceBernstein reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
AllianceBernstein sold 12,063 Sio Gene Therapies Inc. Common Stock shares in Q2 2018, an estimated $128K.
AllianceBernstein first reported a position in Sio Gene Therapies Inc. Common Stock in Q1 2016 and held it in 9 quarters.
AllianceBernstein's Sio Gene Therapies Inc. Common Stock position peaked at $1.21M in Q2 2017.
71 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q2 2018.

Based on AllianceBernstein's 13F filing for Q2 2018, filed 13 Aug 2018.